Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 9, 2004, Pages 1019-1024

  Di Sabatino, A ^a   Ciccocioppo, R ^a   Benazzato, L ^b   Sturniolo, G C ^b   Corazza, G R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROGENESIS; HUMAN; INTESTINAL FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; WOUND HEALING;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2442657641     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01927.x     Document Type: Article

References (23)

1. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
2. Present DH, Rutgeerts P, Targan SR, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
3. van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
4. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase-dependent pathway in Crohn's disease. Gut 2004; 53: 70-8.
5. van Deventer SJH. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001; 121: 1242-6.
6. Toy LS, Scherl EJ, Kornbluth A, et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology 2000; 118: A569.
7. Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFα antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000; 14: 501-4.
8. Rifkin DB, Moscatelli D. Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989; 106: 1-6.
9. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32: 2413-22.
10. Bousvaros A, Zurakowski D, Fishman SJ, et al. Serum basic fibroblast growth factor in pediatric Crohn's disease. Dig Dis Sci 1997; 42: 378-86.
11. Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 504-8.
12. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822-8.
13. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Serum levels of bFGF and VEGF correlate respectively with the ultrasound measurements of bowel wall thickness and the intramural Levovist-enhanced Doppler signal intensity in Crohn's disease. Gastroenterology 2002; 122: A270.
14. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
15. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27-32.
16. Legnani PE, Kornbluth A. Therapeutic options in the management of strictures in Crohn's disease. Gastrointest Endosc Clin N Am 2002; 12: 589-603.
17. Data on file. Malvern PA: Centocor Inc.
18. Li YY, Feng YQ, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. PNAS 2000; 97: 12746-51.
19. Kaidi AA, Nazzal M, Gurchumelidze T, et al. Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation. Am Surg 1995; 61: 569-72.
20. Winberg AM, Rattan S, Lewis JD, et al. Strictures and response to infliximab in Crohn's disease. Am J Gastroenterol 2002; 97: S255.
21. Prajapati DV, Saeian K, Kim JP, et al. Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease. Gastroenterology 2002; 122: A100.
22. 2 Lichtenstein GR, Olson A, Bao W, et al. Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn's disease patients: ACCENT I study results. Am J Gastroenterol 2002; 97: S254.
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.